Fair-Value Report — CSPC Pharmaceutical Group (1093.HK)

Insider Signal

Verified Snapshot

FX: 1 CNY ≈ 1.082 HKD (mid-2026 approximate). All share-price references in HKD; all financials in CNY unless otherwise noted. Sources: CSPC IR (cspc.com.hk), HKEX filings, SmartKarma earnings digest, company annual report 2025.

Business Overview

CSPC Pharmaceutical Group is one of China's largest integrated pharmaceutical companies, founded in 1992 and publicly listed in Hong Kong since 1994. Headquartered in Shijiazhuang, Hebei, it operates across three segments: finished drugs (the engine; ~91% of revenue), bulk active pharmaceutical ingredients (Vitamin C, antibiotics), and functional foods.

Therapeutic focus: The finished-drug portfolio spans neurology (NBP soft capsules for ischemic stroke, a multi-billion CNY franchise), oncology (Duomeisu, Jinyouli), cardiovascular (Xuanning), and anti-infectives. CSPC is executing a deliberate pivot toward innovative/patent-protected drugs — by design its generics and bulk segments are being allowed to decline while the company builds proprietary biologics and small molecules.

FY2025 headwinds explained: China's Volume-Based Procurement (VBP / 集采) programme cut average prices on several flagship generics by 60–80% when included in procurement rounds. The anti-tumor segment fell 60.8% in H1 2025 alone as Duomeisu-related products were hit. Nervous-system products dropped 28.3%. These are not company-specific failures — they are industry-wide VBP impacts that management had flagged as a transition year.

Why the chairman is buying: The working hypothesis (supported by the purchase pattern) is that VBP impacts have largely been absorbed in FY2025 pricing, and the company's innovative pipeline — with several NDA submissions and approvals pending — can drive re-rating. The chairman's cost basis across 2025–2026 purchases averages roughly HK$8.0–8.5, bracketing the current price.

Valuation

Methodology

CSPC is a profitable, cash-generating operating company with a predictable (if currently depressed) earnings base and a growing innovative pipeline. Primary method: three-scenario probability-weighted DCF (25% bull / 50% base / 25% bear) in CNY millions with CAPM WACC, supplemented by P/E and EV/EBITDA peer cross-check.

WACC Derivation (CAPM)

Three-Scenario DCF — Narrative Assumptions

DCF Output — CNY per Share (then converted to HKD)

Net debt = −CNY 8,571M (net cash); diluted shares = 11,400M. HKD conversion at 1 CNY = 1.082 HKD (mid-2026 estimate). Net cash of CNY 0.75/share (HKD 0.81/share) underpins bear case floor.

Reverse DCF — What the Price Implies

At HK$7.07 (CNY 6.53), the market is pricing in approximately 12.1% flat annual revenue growth for 10 years — holding base-case margins, reinvestment intensity, and terminal growth at our assumptions.

Alternatively, the price implies a flat operating margin of approximately 23.5% — compared to our base-case peak of 21% and FY2025's estimated ~19%.

Context: FY2025 revenue fell 10.4%. A 12% CAGR for the next decade is approximately 2× the consensus pharma sector growth rate and assumes flawless execution on innovative drug launches. This is achievable in the bull case but represents the expected outcome, not a scenario with margin of safety.

Peer Comparison

CSPC trades at a 36% premium to peer median P/E (19.2× vs 14.1×) despite negative revenue growth — this premium is NOT justified by current fundamentals. It reflects market pricing of the recovery optionality and the quality of the balance sheet. At peer-median P/E of 14×, CSPC's FY2025 earnings would imply HK$5.2/share. Note: Sino Biopharm's 38× P/E partly reflects its larger innovative pipeline mix. Peer set is small and not perfectly comparable — use as directional cross-check only.

Data sources: Yahoo Finance, TipRanks, Simply Wall St (cross-check only; primary should be company filings). Market caps and P/E approximate as of late May 2026. Peer EV/EBITDA are estimated given D&A unavailability for all peers.

Conclusion & Rating

Rating: SPECULATIVE BUY — for risk-tolerant investors with a 12–18 month horizon and belief in the VBP-cycle recovery thesis.

The honest tension in this report: the probability-weighted DCF values CSPC at HKD 6.38 — approximately 10% below the event-date price of HK$7.07. On pure DCF mechanics, the stock is not cheap. The current price already embeds roughly 12% annual revenue growth for a decade, which is an aggressive ask given a company that just printed −10% revenue.

What tilts the rating to Speculative Buy, rather than Hold or Sell:

• Genuine founder conviction: Cai Dong Chen is not a financial buyer with an exit agenda. He built this company over 33 years. Buying HKD 283M on the open market at what he presumably believes is a trough — on top of CNY 1.2B YTD purchases — is the strongest type of insider signal in our screening framework.
• Fortress balance sheet: Net cash of CNY 8.6B (HKD 0.81/share) and total equity of CNY 34.6B mean the company can sustain current R&D spending and dividend policy (raised 11.5% in FY2025 despite the earnings decline) through a prolonged downturn without dilutive financing.
• VBP trough framing: China's VBP programme impacts are most severe in the first 2–3 years after inclusion. If the chairman's assessment is correct that FY2025 absorbed the worst, FY2026–2027 should see base effects reverse. The anti-tumor segment's 60% decline in H1 2025 cannot persist indefinitely.
• Bull case is plausible: In the bull scenario (innovative drugs re-rate, VBP normalised), DCF supports HKD 8.93 — a 26% return from the event date.

Signal vs price verdict: The signal is real. The price is full. This is a recovery bet, not a value trap exit. Appropriate position size is sub-normal (half-weight) given the DCF base case is below the current price and the bear case (HKD 3.96) represents significant downside if the recovery is delayed by new VBP rounds or pipeline failures.

Key Risks

• VBP expansion: Additional CSPC drugs included in national procurement rounds could extend the revenue decline beyond FY2026, invalidating the base-case recovery. This is the single biggest risk.
• Pipeline setbacks: If innovative drug approvals are delayed or fail Phase III, the re-rating thesis collapses — the business reverts to a commoditising generics operator.
• CNY depreciation: Reported HKD returns are diluted if the CNY weakens materially against the HKD peg.
• Regulatory / pricing: China's healthcare reform remains ongoing. Unexpected price cuts on NBP (the largest revenue product) or cardiovascular drugs would sharply compress margins.
• Nominee opacity: While Cai Dong Chen is the disclosed filer, the actual share ownership may be held through family vehicles. The economic intent is clear from context, but future family estate or succession decisions could introduce selling pressure.
• Valuation ceiling: Even in the bull scenario (HKD 8.93), the upside from current levels is modest. If the stock has already re-rated from the HK$7.07 event date to HK$8–9+, the risk/reward is materially less attractive and the rating should be reconsidered as Hold.
• Data limits: Capex is not confirmed from company filings; EBITDA and EBIT are estimated from net profit margin and implied tax bridge. These inputs could shift DCF output by 5–10%.

Sources

• CSPC Pharmaceutical Group — Investor Relations (cspc.com.hk/en/ir), FY2025 Annual Results
• HKEX Disclosure of Interests database — Cai Dong Chen filing, 2026-05-28
• SmartKarma earnings alerts — FY2025 revenue and EPS verification
• Minichart.com.sg — FY2025 annual report summary (balance sheet)
• Yahoo Finance / TipRanks / Simply Wall St — price, beta, dividend cross-checks (English aggregators used as supplementary only)
• Damodaran NYU Stern data tables — ERP, CRP (pages.stern.nyu.edu/~adamodar)
• HKMA / Trading Economics — HK 10Y bond yield (May 2026)
• Futunn News — prior insider purchase disclosures (2025–2026 context)
• DCF and reverse DCF computed via openclaw/stock-valuation scripts (dcf.py, reverse_dcf.py, wacc.py); not computed by hand